Stock Ratings / Health Care / RNAZ / options

RMTI (28) BCTX (41) NXTC (48) CPHI (45) ⌘ Pro Terminal →

TransCode Therapeutics Inc. (RNAZ) Options Positioning, Max Pain & Unusual Sweeps

$1.73 -0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

TransCode Therapeutics Inc. (RNAZ) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $29.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNAZ)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RNAZ)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RNAZ.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNAZ)

✓Walkthrough of RNAZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RNAZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.40%▲ RESISTANCE BREAKOUT

2026-10-30O $1.73H $1.78L $1.62C $1.73VOL 16.1K

RES: $1.20SUP: $0.58SMA50: $1.83SMA200: $6.15

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNAZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNAZ Butterfly Map → + Track RNAZ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNAZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNAZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RNAZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNAZ)

Health Care Rank #422 of 1016 ⚔️ RMTI vs RNAZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNAZ vs. RMTI, BCTX, NXTC, CPHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TransCode Therapeutics Inc. (RNAZ) ranks #422 by composite RQD confidence (47/100, grade D) and #807 by equity capitalization ($29.3M). Within this direct 5-issuer industry benchmark cohort, RNAZ leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RNAZ at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RNAZ ACTIVE TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	Benchmark Subject
RMTI Rockwell Medical Inc.	E	28/100	—	16.9%	-10.6%	0.00%	$29.5M	/rmti-vs-rnaz →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-rnaz →
NXTC NextCure Inc.	D	48/100	—	—	-35.0%	+2.92%	$29.9M	/nxtc-vs-rnaz →
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-rnaz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001829635

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TransCode Therapeutics Inc. (RNAZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.7M, operating cash flow of -$19.5M, and free cash flow of -$19.5M (-46.2% YoY). On the balance sheet, RNAZ closed FY2025 with $162.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$34.7M	-$19.5M	-$19.5M	$162.4M	—
FY2024 (FY)	2024-12-31	$0	-$16.8M	-$13.3M	-$13.4M	$7.3M	—
FY2023 (FY)	2023-12-31	$0	-$18.5M	-$18.1M	-$18.1M	—	—

3. RNAZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNAZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, TransCode Therapeutics Inc. (NASDAQ: RNAZ) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.73 (-0.57% 1D, market cap $29.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RNAZ ranks #422 in composite RQD confidence.

How does RNAZ compare to RMTI and BCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAZ carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RMTI (Rockwell Medical Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -10.6%, cap $29.5M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (41/100 RQD, P/E N/A, ROIC —, cap $28.9M). Among the 5-stock peer group, RNAZ leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNAZ?

Per RNAZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001829635), TransCode Therapeutics Inc. generated $0 in revenue, -$34.7M in net income, and -$19.5M in free cash flow against $162.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNAZ trading relative to its 50-day, 200-day, and 52-week technical levels?

RNAZ last traded at $1.73 (-0.57% on volume of 40,841 shares), positioning the stock -5.46% below its 50-day simple moving average ($1.83) and -71.87% below its 200-day simple moving average ($6.15). Across its 52-week range of $1.52 to $12.60, RNAZ sits at the 1.9% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.51 to $1.95).

RNAZ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RNAZ's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for RNAZ.

Direct Sub-Reports: RNAZ RQD Cockpit RNAZ 12M Forecast RNAZ Earnings & Move RNAZ Dividends & DRIP RNAZ Insiders & 13F RNAZ Whale Options RNAZ Profit Sankey RNAZ News & Why